<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303094</url>
  </required_header>
  <id_info>
    <org_study_id>T-DIS-1001</org_study_id>
    <nct_id>NCT01303094</nct_id>
  </id_info>
  <brief_title>Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma</brief_title>
  <acronym>T-DIS</acronym>
  <official_title>Phase II Randomized Trial to Evaluate Two Strategies: Continuing Versus Intermittent (Drug-holiday) Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the Sixth Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Sarcome Français</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe d’études des Tumeurs Osseuses</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomization discontinuation trial will allow for concomitant evaluation of the
      following:

        -  Side effects and benefits of immediate continuation of Trabectedin after the sixth cycle

        -  Side effects and benefits of a drug holiday
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selection part (220 patients):

      Trabectedin (depending on dose reductions : between 1.5 and 1 mg/m²/3 weeks; over 24 hour
      administration) until progression, intolerance or 6 cycles (according to the SPC of
      Trabectedin)

      Randomized part (50 patients):

      After the 6 first cycles, if there is not progression or unacceptable toxicity, the patients
      will be randomly assigned to continuous or &quot;intermittent/holiday&quot; therapy with CT-scan
      evaluation every 6 weeks in both arms

        -  Arm A Continuation of Trabectedin (between 1.5 and 1 mg/m²/3 weeks; over 24 hour
           administration) until progression or intolerance

        -  Arm B &quot;Intermittent/holiday&quot; therapy. Rechallenge of Trabectedin will be implemented in
           the event of progression; in this case administration of Trabectedin will occur until
           the second progression or intolerance
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS rate 24 weeks after randomization</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>In each arms among non progressive patients after the 6 first cycles of Trabectedin : occurrence of progression or death 24 weeks after the date of randomization. Intention to treat analysis. Centralised radiological review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6, 12 and 18 weeks after randomization</time_frame>
    <description>stabilisation, complete and partial responses according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rates</measure>
    <time_frame>12 and 54 weeks after randomization</time_frame>
    <description>According to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rates</measure>
    <time_frame>12 and 24 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free and median overall survivals</measure>
    <time_frame>Up to 5 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Up to 30 days after the last study drg administration</time_frame>
    <description>According to NCI-CTC V4.0 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological predictive factors for non progression at the 6th cycle</measure>
    <time_frame>At baseline</time_frame>
    <description>Collected data at baseline : age, gender, comorbidity, disease history, previous treatment, tumor description, biological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-randomization cost of care</measure>
    <time_frame>For one year after randomization</time_frame>
    <description>Cost of care will be evaluated by macro-costing approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self estimation of general health status</measure>
    <time_frame>For 1 year after randomization</time_frame>
    <description>Evaluation every 6 weeks by 100-mm-long horizontal visual analog scale (VAS) that ranged from worst imaginable health (as bad as death, 0) to perfect health</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Uterine Sarcoma</condition>
  <arm_group>
    <arm_group_label>Continuation of Trabectedin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Drug holiday&quot; therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.</description>
    <arm_group_label>Continuation of Trabectedin</arm_group_label>
    <other_name>Yondelis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Drug: holiday</intervention_name>
    <description>A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.</description>
    <arm_group_label>&quot;Drug holiday&quot; therapy</arm_group_label>
    <other_name>No drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for the selection part):

          -  Inoperable or metastatic soft tissue sarcoma and/or uterine sarcoma

          -  Measurable lesions (RECIST 1.1)

          -  Performance status ≤ 2

          -  Age ≥ 18

          -  Normal hematological parameters (polynuclear neutrophils ≥ 1500, hemoglobin level ≥ 9
             g/dl, platelets counts ≥ 100,000)

          -  Adequate biological parameters :

          -  Adequate hepatic function (bilirubin ≤ ULN , SGPT/ALT and SGOT/AST ≤ 2.5 x ULN)

          -  Alkaline phosphatases ≤ 2.5 x ULN, If Alkaline phosphatases ≥ 2.5 ULN, hepatic
             isoenzymes 5-nucleotidases or GGT tests must be performed; hepatic isoenzymes 5-
             nucleotidases and/or GGT must be within the normal range

          -  Albumin ≥ 25 g/L

          -  Adequate renal function : Serum creatinine ≤ 1.5 x ULN

          -  Creatine phosphokinase ≤ 2.5 x ULN

          -  Adequate central venous access

          -  Pregnant or lactating women or men of reproductive potential must use effective
             contraceptive methods

          -  Patient covered by government health insurance

          -  Information sheet given to the patient (Patient information sheet 1)

        Exclusion Criteria (for the selection part):

          -  Patients that have received more than one regimen of chemotherapy for metastatic or
             inoperable soft tissue or uterine sarcoma, after the failure/intolerance of
             doxorubicin and ifosfamide. Maintenance treatment does not count as treatment line

          -  The following histological subtypes : GIST, rhabdomyosarcoma, aggressive fibromatosis,
             desmoïd tumour, PNET, carcinosarcoma, and all bone sarcomas

          -  Single tumour in an irradiated region

          -  Other malignant tumour over the past five years (except basal cell carcinoma or
             cervical carcinoma in situ adequately treated)

          -  Currently active bacterial or fungus infection (&gt; grade 2 CTC [CTCAE] Version 4.02).
             Known HIV1, HIV2, hepatitis B or hepatitis C infections

          -  Presence of known leptomeningeal or brain metastasis

          -  Patients unable to receive corticotherapy

          -  Any circumstance that could jeopardise compliance or proper follow-up during the trial

          -  Pregnant or nursing women

        Inclusion Criteria (for the randomized part):

          -  Patient registered in the selection part

          -  Stable tumour or objective response (CR + PR) after 6 Trabectedin (Yondelis®) cycles,
             according to local assessment

          -  Available copies of thoraco-abdominal and pelvic scan performed prior to the first
             cycle and after the sixth cycle

          -  Performance status ≤ 2

          -  Patients receiving at least 1 mg/m²/3 weeks of Trabectedin at the time of the sixth
             cycle

          -  Normal hematological parameters (polynuclear neutrophils ≥ 1500, hemoglobin level ≥ 9
             g/dl, platelets counts ≥ 100,000)

          -  Adequate biological parameters :

          -  Adequate hepatic function (bilirubin ≤ ULN , SGPT/ALT and SGOT/AST ≤ 2.5 x ULN)

          -  Alkaline phosphatases ≤ 2.5 x ULN, If Alkaline phosphatases ≥ 2.5 ULN, hepatic
             isoenzymes 5-nucleotidases or GGT tests must be performed; hepatic isoenzymes 5-
             nucleotidases and/or GGT must be within the normal range

          -  Albumin ≥ 25 g/L

          -  Adequate renal function : Serum creatinine ≤ 1.5 x ULN

          -  Creatine phosphokinase (CPK) ≤ 2.5 x ULN

          -  Adequate central venous access

          -  Pregnant or lactating women or men of reproductive potential must use effective
             contraceptive methods

          -  Informed consent form signed by the patient or the patient's legal representative
             (patient information sheet 2 and informed consent)

        Exclusion Criteria (for the randomized part):

          -  Tumour progression (according to RECIST 1.1) during the first six Yondelis cycles

          -  Non-availability of baseline scans prior to the first cycle and following the sixth
             cycle

          -  Currently active bacterial or fungus infection (&gt; grade 2 CTC [CTCAE] Version 4.02).
             Known HIV1, HIV2, hepatitis B or hepatitis C infections

          -  Presence of known leptomeningeal or brain metastasis

          -  Creatinine clearance less than 30 ml/min

          -  Patients unable to receive corticotherapy

          -  Any circumstance that could jeopardise compliance or proper follow-up during the trial

          -  Pregnant or nursing women

          -  Hypersensitivity to Trabectedin or any excipient in prior cycles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas PENEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint-Jacques Hospital</name>
      <address>
        <city>Besancon</city>
        <zip>25 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Léon Bérard Center</name>
      <address>
        <city>Lyon</city>
        <zip>69 008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paoli Calmette Institute</name>
      <address>
        <city>Marseille</city>
        <zip>13 273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>St Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

